<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402493</url>
  </required_header>
  <id_info>
    <org_study_id>GA6110HV</org_study_id>
    <nct_id>NCT00402493</nct_id>
  </id_info>
  <brief_title>Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops</brief_title>
  <official_title>A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philadelphia Eye Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Philadelphia Eye Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of This Study is to Determine if Taking an Over the Counter Non-Steroidal
      Anti-Inflammatory(Ibuprofen)has an Effect on Eye Pressure in Patients using
      Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Topical IOP-lowering therapy has the advantage of providing a drug level directly to the end
      organ with very little or no systemic absorption thereby reducing side effect potential.
      There is very little information in the ophthalmic literature regarding potential drug
      interactions between topical IOP-lowering medications and other medications taken orally for
      other medical reasons. Patients will be randomized to either latanoprost or brimonidine.
      Patients in both groups will be randomized to either placebo or ibuprofen for the first 14
      days and then crossed over to the other treatment for 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen, latanoprost, brimonidine</intervention_name>
    <description>to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure</description>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_label>Brimonidine</arm_group_label>
    <arm_group_label>ibuprofen</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen, brimonidine, latanoprost</intervention_name>
    <description>to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure</description>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_label>Brimonidine</arm_group_label>
    <other_name>ibuprofen 200mg, and placebo pills</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>ibuprofen 200mg</description>
    <arm_group_label>ibuprofen</arm_group_label>
    <other_name>ibuprofen 200mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with bilateral or unilateral primary open angle glaucoma or ocular
             hypertension

          -  An IOP in each eye of greater than 22mm HG after washout of IOP lowering medications

          -  No worse than 20/200 best corrected visual acuity

          -  Normal appearing or non-occludable anterior chamber angles

          -  Discontinuation of current POAG or OH medications before participation in the study.

          -  Written Informed Consent

        Exclusion Criteria:

          -  Use of any other ocular medications

          -  Previous ocular surgery or laser therapy within the last three months.

          -  Systemic treatment with any adrenergic agonist or antagonist, corticosteroid or
             nonsteroidal anti-inflammatory agents(low dose apsirin will be accepted if dose
             remains the same for entire study period).

          -  An age of less than 21,of child bearing age and currently pregnant, considering
             pregnancy or a nursing mother.

          -  A history of medical noncompliance or unreliability.

          -  Presence of uncontrolled hypertension, cardiac arrhythmia, cerebrovascular accident,
             nasal polyps, bleeding diathesis, peptic ulcer disease, gastritis or known
             intolerance, contraindication or allergy to any drugs used in the study.

          -  Lactose Intolerance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph I. Markoff, Ph.D,M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia Eye Associates</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Eye Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Eye Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>Xalatan</keyword>
  <keyword>Alpahgan</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Non-Steroidal Anti-Inflammatory</keyword>
  <keyword>Brimonidine</keyword>
  <keyword>Latanoprost</keyword>
  <keyword>Eye Pressure</keyword>
  <keyword>Intra-Ocular Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

